Literature DB >> 2883332

Comparative study of tiapride and neuroleptics with anti-dopamine activity on convulsive seizure in mice.

H Satoh, H Nakanishi, K Shirakawa, Y Kohjimoto, T Kuwaki, T Ono, F Shibayama.   

Abstract

The effects of tiapride on the convulsive seizures induced by pentylenetetrazole, strychnine, picrotoxin and bemegride, and on electric seizure are reported and compared with those of sulpiride, chlorpromazine, haloperidol and reserpine. The number of deaths and intensity of convulsion increased dose-dependently and also with the increase in amplitude of electric shock. Tiapride and a similar compound, sulpiride, did not affect these seizures, whereas chlorpromazine potentiated strychnine-induced and electric seizure. Haloperidol and reserpine potentiated electric seizure, and chlorpromazine and reserpine tended to potentiate bemegride-induced seizure. Reserpine also tended to potentiate pentylenetetrazole-induced seizure. These results suggest that tiapride would be clinically safer than other drugs with anti-dopamine activity, except for sulpiride.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2883332     DOI: 10.1254/jjp.43.27

Source DB:  PubMed          Journal:  Jpn J Pharmacol        ISSN: 0021-5198


  3 in total

1.  Tiapride pre-treatment in acute exposure to paraoxon: comparison of effects of administration at different points-in-time in rats.

Authors:  G A Petroianu; M Y Hasan; S M Nurulain; K Arafat; M Shafiullah; R Sheen
Journal:  Mol Cell Biochem       Date:  2006-02-15       Impact factor: 3.396

Review 2.  Tiapride. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in geriatric agitation.

Authors:  J W Steele; D Faulds; E M Sorkin
Journal:  Drugs Aging       Date:  1993 Sep-Oct       Impact factor: 3.923

Review 3.  Tiapride. A review of its pharmacology and therapeutic potential in the management of alcohol dependence syndrome.

Authors:  D H Peters; D Faulds
Journal:  Drugs       Date:  1994-06       Impact factor: 9.546

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.